Physician profile
Kristin Miller
NPI 1023378650
$3,674.09
in general payments reported to CMS, 2019-2025
28 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,517 · 2020: $357 · 2021: $360 · 2022: $444 · 2023: $247 · 2024: $288 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $898 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $898.06 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $524.59 | 2019-2025 | |
| Astellas Pharma US INC | $328.45 | 2019-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $318.92 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.67 | 2019-2025 | Jardiance, Synjardy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $251.16 | 2019 | |
| Novo Nordisk INC | $245.53 | 2019-2025 | Ozempic |
| Astrazeneca Pharmaceuticals LP | $212.40 | 2019-2021 | |
| Genentech USA, INC. | $188.97 | 2019-2020 | |
| Abbvie INC. | $184.40 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $184.36 | 2019-2020 | |
| Abbott Laboratories | $139.43 | 2021-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $138.74 | 2019-2021 | |
| Glaxosmithkline, LLC. | $128.69 | 2019-2025 | Shingrix, Trelegy Ellipta |
| Dexcom, INC. | $121.09 | 2022-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $85.63 | 2019-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $74.13 | 2019-2020 | |
| Amgen INC. | $45.11 | 2019 | |
| Hologic Sales and Service, LLC | $39.58 | 2024 | Thinprep 2000 Processor, Aptima |
| Janssen Pharmaceuticals, INC | $27.32 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $27.05 | 2019 | |
| Allergan, INC. | $24.03 | 2019 | |
| Edwards Lifesciences Corporation | $22.13 | 2023 | |
| Sumitomo Pharma America, INC. | $19.39 | 2025 | Gemtesa |
| Supernus Pharmaceuticals, INC. | $14.50 | 2025 | Qelbree |
| Exact Sciences Corporation | $14.00 | 2025 | Cologuard Collection Kit |
| Medtronic, INC. | $13.94 | 2023 | Intellis Adaptivestim |
| Teva Pharmaceuticals USA, INC. | $12.64 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.